Arch Biopartners Adds Farris Smith as a Strategic Advisor
October 05, 2022 07:20 ET
|
Arch Biopartners
TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of...
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials
August 05, 2022 07:30 ET
|
Arch Biopartners
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with...
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)
February 14, 2022 07:30 ET
|
Arch Biopartners
TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
Shares for Interest Debt Settlement
February 08, 2022 19:44 ET
|
Arch Biopartners
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt...
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury
February 03, 2022 07:30 ET
|
Arch Biopartners
TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at...
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
January 04, 2022 07:25 ET
|
Arch Biopartners
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial
December 01, 2021 07:35 ET
|
Arch Biopartners
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant...
Le peptide LSALT, principal médicament d'Arch Biopartners, entre dans l'essai canadien sur les traitements contre la COVID-19 (CATCO)
December 01, 2021 07:30 ET
|
Arch Biopartners
Le peptide LSALT (LSALT) est un nouveau candidat médicament en cours de développement pour cibler l'inflammation aiguë des organes dans les poumons, le foie et les reins qui est courante dans les cas...
Unaware of Any Undisclosed Material Change
October 15, 2021 10:42 ET
|
Arch Biopartners
TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and...
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide
August 05, 2021 06:30 ET
|
Arch Biopartners
TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...